Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EBT (2016 - 2025)

Historic EBT for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to -$30.6 million.

  • Avalo Therapeutics' EBT fell 23297.14% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.7 million, marking a year-over-year decrease of 115177.61%. This contributed to the annual value of -$35.0 million for FY2024, which is 1105.3% down from last year.
  • As of Q3 2025, Avalo Therapeutics' EBT stood at -$30.6 million, which was down 23297.14% from -$20.7 million recorded in Q2 2025.
  • In the past 5 years, Avalo Therapeutics' EBT ranged from a high of $98.5 million in Q2 2024 and a low of -$121.3 million during Q1 2024
  • Moreover, its 5-year median value for EBT was -$13.1 million (2025), whereas its average is -$13.5 million.
  • Data for Avalo Therapeutics' EBT shows a peak YoY increase of 130290.74% (in 2024) and a maximum YoY decrease of 111929.22% (in 2024) over the last 5 years.
  • Avalo Therapeutics' EBT (Quarter) stood at -$19.1 million in 2021, then soared by 48.8% to -$9.8 million in 2022, then grew by 16.6% to -$8.2 million in 2023, then crashed by 330.78% to -$35.2 million in 2024, then increased by 13.09% to -$30.6 million in 2025.
  • Its EBT stands at -$30.6 million for Q3 2025, versus -$20.7 million for Q2 2025 and -$13.1 million for Q1 2025.